Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VIRX)

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 10 days ago

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

GlobeNewswire November 6, 2024

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

GlobeNewswire August 14, 2024

Viracta Therapeutics Announces New Employment Inducement Grants

GlobeNewswire May 17, 2024

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire May 14, 2024

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2024
View More News ››

Opinion & Analysis (NDAQ:VIRX)

Sunesis Pharmaceuticals shifts focus to leukemia drug

The Life Sciences Report May 18, 2017

How three companies have been resurrected from failed clinical trials:George Zavoico of JonesTrading

The Life Sciences Report April 6, 2016

BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

Gail Dutton October 1, 2015

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015

Novel technology platforms with dramatic growth potential: Wedbush's David Nierengarten

George S. Mack August 26, 2015

Capitalize on comeback stories in micro-cap biotech: Joe Pantginis of ROTH Capital Partners

George S. Mack June 17, 2015
View More Opinion ››

Bullboard Posts (NDAQ:VIRX)

Viracta Therapeutics to Present at the H.C. Wainwright 26th

News; $VIRX Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSAN DIEGO, Sept. 03, 2024...
whytestocks - September 3, 2024

Viracta Therapeutics, Inc. (NASDAQ:VIRX): A Promising Precis

http://beyondspx.com/2024/08/02/viracta-therapeutics-inc-nasdaqvirx-a-promising-precision-oncology-company-focused-on-virus-associated...
MikeTester - August 3, 2024

<<<<<<

SNSS has lost market share by growing sales slower than the industry average. This trend continues from the previous year when sales...
Trader24 - April 7, 2015

SNSS...////

People continue to watch SNSS but it’s unlikely that it will have enough momentum to break resistance at...
Michael879 - October 21, 2010

RE: SNSS..>>>>>

Very curious where this is headed in the near future
travelsee - October 20, 2010

SNSS..>>>>>

SNSSmanaged to push higher yesterday but the price continues to run intoresistance just below .35. Because volume remains strong, people...
jhonson890 - October 20, 2010
View more Bullboard ››

Fintech Select Ltd.

Fintech Select Ltd.

Fintech Select is a provider of pre-paid card programs, an online payment platform, and a POS cryptocurrency platform that ...
View More »